Hepatitis C is caused by infection with the Hepatitis C virus (HCV). Transmission is predominately through the blood-to blood route where persons such as current or former injection drug users, past recipients of blood transfusions or solid organ transplants and chronic hemodialysis patients are examples of risk groups. HCV infection becomes chronic in 75-85% of cases and if left untreated can result in chronic liver disease, cirrhosis and hepatocellular carcinoma (HCC). The WHO estimates that about 3% of the world's population has been infected with HCV and that some 170 million are chronic carriers at risk.
This MarketVIEW product contains two comprehensive MS Excel-based models + summary presentation which forecast the potential commercial value of Hepatitis C Virus (HCV) TX and PX vaccines across major Western markets until 2030. The models contain value ($ m) and volume (mio doses) predictions per product type along with timeframe, pricing and penetration estimates for all adult risk groups. The product also includes an in depth review of latest HCV epidemiological trends, developments in new antivirals and immunological based treatments.
THIS PRODUCT IS A EXECUTIVE PRESENTATION + 2 MODELS